Related Experiment Video
Updated: Aug 18, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma
Hiromi Nagano1, Satoshi Kiyama1, Takayuki Kyutoku1
1Department of Otolaryngology-Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Objectives:
The purpose of this study is to investigate the genetic mutational status of recurrent/metastatic papillary thyroid carcinoma (PTC) and its prognostic implications.
Methods:
Data were analyzed for 348 consecutive patients with PTC registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C-CAT) between June 2019 and February 2026. Genetic mutations were determined by next generation sequencing. Survival of patients was determined by log-rank test and a Cox proportional hazards model.
Results:
The top 10 mutations in recurrent/metastatic PTC were TERT (82.2%), BRAF (78.7%), LTK (16.1%), CDKN2A (15.2%), KMT2D (14.4%), NOTCH3 (14.1%), TP53 (12.9%), PIK3CA (11.5%), CDKN2B (10.6%), STK11 (10.3%), with 11.0 ± 0.19 (mean ± SEM) mutations/individual. BRAF (p = 0.0379), CDKN2A (p = 7.41 × 10-12), KMT2D (p = 0.0048), PIK3CA (p = 0.0406), CDKN2B (p = 7.24 × 10-13), and concurrent TERT/BRAF (p = 0.0141) were associated with a significantly worse prognosis, as determined by log-rank test. Multivariable Cox proportional hazards analysis was 3.762 (95% CI, 1.7480-8.095; p = 7.026 × 10-4) for CDKN2A, 2.620 (1.50-4.575; p = 7.076 × 10-4) for KMT2D, 1.882 (1.127-3.143; p = 0.01572) for concurrent TERT/BRAF.
Conclusions:
This study delineated the mutational spectrum of recurrent and/or metastatic PTC and identified several alterations with significant prognostic relevance. Even in advanced disease, specific mutations such as CDKN2A, KMT2D, and concurrent TERT/BRAF remained strongly associated with poor survival, underscoring the clinical value of comprehensive cancer genomic profiling in this population.
Related Concept Videos
Cancers Originate from Somatic Mutations in a Single Cell
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

